According to a recent LinkedIn post from Phantom Neuro, the company’s first-in-human clinical study, named CYBORG, for its Phantom X system has received approval in Australia. The post indicates that the trial aims to advance prosthetic and robotic hand technologies toward more natural, intuitive movement for individuals with limb loss.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post notes that up to 10 adult upper limb amputee participants are expected to be enrolled in Melbourne, with surgical procedures to occur at Cabrini Health and prosthetic care and rehabilitation to be provided by ProMotion Prosthetics and Enable Rehab. Links in the post direct interested individuals to additional study information and a participation registry.
From an investor perspective, the approved CYBORG study suggests Phantom Neuro is transitioning from development toward early clinical validation of its neurotechnology platform. Successful execution and positive data could enhance the company’s technological credibility, support future regulatory pathways, and potentially strengthen its position in the neurotech and advanced prosthetics market.
The collaboration with established clinical and rehabilitation partners in Australia may also help Phantom Neuro build a reference network for future commercialization efforts. However, as with any early clinical study, revenue implications remain long term and contingent on clinical outcomes, scalability of the technology, and eventual reimbursement and adoption dynamics in target healthcare systems.